Joanne B Weidhaas

Title(s)Professor, Radiation Oncology
SchoolMedicine
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    Germ-line miRNA binding site variants as biomarkers of toxicity and response to checkpoint inhibition
    NIH R01CA238998May 1, 2019 - Apr 30, 2024
    Role: Principal Investigator
    MicroRNAs to Understand Cause and Outcome in Breast Cancer
    NIH R01CA157749Jul 1, 2012 - May 31, 2017
    Role: Principal Investigator
    Let-7 microRNAs in Lung Cancer: Altering Growth and Radioresistance
    NIH R01CA131301Mar 5, 2009 - Jan 31, 2014
    Role: Principal Investigator
    Defining the Genetic Basis of the Radioresponse Using a C. elegans Tissue Model
    NIH K08CA124484Sep 18, 2007 - Aug 31, 2012
    Role: Principal Investigator
    The UCLA Center for Medical Countermeasures Against Radiation
    NIH U19AI067769Aug 31, 2005 - Jul 31, 2021
    Role: Co-Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. ASO Visual Abstract: Epigenetic Signatures Predict Pathologic Nodal Stage in Breast Cancer Patients with Estrogen-Receptor-Positive, Clinically Node-Positive Disease. Ann Surg Oncol. 2022 Apr 16. Ensenyat-Mendez M, Rünger D, Orozco JIJ, Le J, Baker JL, Weidhaas J, Marzese DM, DiNome ML. PMID: 35430657.
      View in: PubMed   Mentions:
    2. Epigenetic Signatures Predict Pathologic Nodal Stage in Breast Cancer Patients with Estrogen Receptor-Positive, Clinically Node-Positive Disease. Ann Surg Oncol. 2022 Apr 09. Ensenyat-Mendez M, Rünger D, Orozco JIJ, Le J, Baker JL, Weidhaas J, Marzese DM, DiNome ML. PMID: 35397740.
      View in: PubMed   Mentions:
    3. Viral Burden and Clearance in Asymptomatic COVID-19 Patients. Open Forum Infect Dis. 2022 May; 9(5):ofac126. Gunatilaka AB, Marco N, Read GH, Sweeney M, Regan G, Tsang C, Abdulrahman L, Ampabathina S, Spindler A, Lu SS, Schink E, Gatti R, Ingersoll C, Telesca D, Weidhaas JB. PMID: 35493121; PMCID: PMC8992297.
      View in: PubMed   Mentions:
    4. Germline biomarkers predict toxicity to anti-PD1/PDL1 checkpoint therapy. J Immunother Cancer. 2022 02; 10(2). Weidhaas J, Marco N, Scheffler AW, Kalbasi A, Wilenius K, Rietdorf E, Gill J, Heilig M, Desler C, Chin RK, Kaprealian T, McCloskey S, Raldow A, Raja NP, Kesari S, Carrillo J, Drakaki A, Scholz M, Telesca D. PMID: 35115362; PMCID: PMC8804679.
      View in: PubMed   Mentions:
    5. Germline variants disrupting microRNAs predict long-term genitourinary toxicity after prostate cancer radiation. Radiother Oncol. 2022 Feb; 167:226-232. Kishan AU, Marco N, Schulz-Jaavall MB, Steinberg ML, Tran PT, Juarez JE, Dang A, Telesca D, Lilleby WA, Weidhaas JB. PMID: 34990726; PMCID: PMC8979583.
      View in: PubMed   Mentions:
    6. Transcriptomic Heterogeneity of Gleason Grade Group 5 Prostate Cancer. Eur Urol. 2020 09; 78(3):327-332. Kishan AU, Romero T, Alshalalfa M, Liu Y, Tran PT, Nickols NG, Ye H, Sajed D, Rettig MB, Reiter RE, Garraway IP, Spratt DE, Freedland SJ, Zhao X, Li Z, Deek M, Livingstone J, Mahal BA, Nguyen PL, Feng FY, Den RB, Schaeffer EM, Lotan TL, Karnes RJ, Klein EA, Ross AE, Grogan T, Davicioni E, Elashoff D, Boutros PC, Weidhaas JB. PMID: 32461072; PMCID: PMC8954568.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    7. Development and Validation of a Comprehensive Multivariate Dosimetric Model for Predicting Late Genitourinary Toxicity Following Prostate Cancer Stereotactic Body Radiotherapy. Front Oncol. 2020; 10:786. Valle LF, Ruan D, Dang A, Levin-Epstein RG, Patel AP, Weidhaas JB, Nickols NG, Lee PP, Low DA, Qi XS, King CR, Steinberg ML, Kupelian PA, Cao M, Kishan AU. PMID: 32509582; PMCID: PMC7251156.
      View in: PubMed   Mentions:
    8. A Phase II Trial of 5-Day Neoadjuvant Radiotherapy for Patients with High-Risk Primary Soft Tissue Sarcoma. Clin Cancer Res. 2020 04 15; 26(8):1829-1836. Kalbasi A, Kamrava M, Chu FI, Telesca D, Van Dams R, Yang Y, Ruan D, Nelson SD, Dry SM, Hernandez J, Chmielowski B, Singh AS, Bukata SV, Bernthal NM, Steinberg ML, Weidhaas JB, Eilber FC. PMID: 32054730; PMCID: PMC7189949.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    9. Identifying MicroRNA Pathway Variants as Biomarkers of Patient Selection for Immune Therapy. Methods Mol Biol. 2020; 2055:203-212. Weidhaas JB. PMID: 31502153.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    10. Correction to: Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. J Immunother Cancer. 2019 Jul 04; 7(1):167. Bedognetti D, Ceccarelli M, Galluzzi L, Lu R, Palucka K, Samayoa J, Spranger S, Warren S, Wong KK, Ziv E, Chowell D, Coussens LM, De Carvalho DD, DeNardo DG, Galon J, Kaufman HL, Kirchhoff T, Lotze MT, Luke JJ, Minn AJ, Politi K, Shultz LD, Simon R, Thórsson V, Weidhaas JB, Ascierto ML, Ascierto PA, Barnes JM, Barsan V, Bommareddy PK, Bot A, Church SE, Ciliberto G, De Maria A, Draganov D, Ho WS, McGee HM, Monette A, Murphy JF, Nisticò P, Park W, Patel M, Quigley M, Radvanyi L, Raftopoulos H, Rudqvist NP, Snyder A, Sweis RF, Valpione S, Zappasodi R, Butterfield LH, Disis ML, Fox BA, Cesano A, Marincola FM, Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Group. PMID: 31272507; PMCID: PMC6610889.
      View in: PubMed   Mentions: 1     Fields:    
    11. Lack of an Association between a Polymorphism in the KRAS 3' Untranslated Region (rs61764370) and Endometriosis in a Large European Case-Control Study. Gynecol Obstet Invest. 2019; 84(6):575-582. D'Hooghe TM, Grechukhina O, Cho S, Fassbender A, O D, Peterse D, Weidhaas J, Taylor HS. PMID: 31185482.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    12. Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. J Immunother Cancer. 2019 05 22; 7(1):131. Bedognetti D, Ceccarelli M, Galluzzi L, Lu R, Palucka K, Samayoa J, Spranger S, Warren S, Wong KK, Ziv E, Chowell D, Coussens LM, De Carvalho DD, DeNardo DG, Galon J, Kaufman HL, Kirchhoff T, Lotze MT, Luke JJ, Minn AJ, Politi K, Shultz LD, Simon R, Thórsson V, Weidhaas JB, Ascierto ML, Ascierto PA, Barnes JM, Barsan V, Bommareddy PK, Bot A, Church SE, Ciliberto G, De Maria A, Draganov D, Ho WS, McGee HM, Monette A, Murphy JF, Nisticò P, Park W, Patel M, Quigley M, Radvanyi L, Raftopoulos H, Rudqvist NP, Snyder A, Sweis RF, Valpione S, Zappasodi R, Butterfield LH, Disis ML, Fox BA, Cesano A, Marincola FM, Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Group. PMID: 31113486; PMCID: PMC6529999.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansAnimals
    13. Enhancing Career Paths for Tomorrow's Radiation Oncologists. Int J Radiat Oncol Biol Phys. 2019 09 01; 105(1):52-63. Vapiwala N, Thomas CR, Grover S, Yap ML, Mitin T, Shulman LN, Gospodarowicz MK, Longo J, Petereit DG, Ennis RD, Hayman JA, Rodin D, Buchsbaum JC, Vikram B, Abdel-Wahab M, Epstein AH, Okunieff P, Goldwein J, Kupelian P, Weidhaas JB, Tucker MA, Boice JD, Fuller CD, Thompson RF, Trister AD, Formenti SC, Barcellos-Hoff MH, Jones J, Dharmarajan KV, Zietman AL, Coleman CN. PMID: 31128144; PMCID: PMC7084166.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    14. The KRAS-variant and its impact on normal breast epithelial cell biology. Cell Death Differ. 2019 12; 26(12):2568-2576. Jung SY, Malhotra P, Nguyen KC, Salzman D, Qi Y, Pak EH, King J, Vlashi E, Ann D, Weidhaas JB. PMID: 30932013; PMCID: PMC7224195.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    15. Breast Cancer and miR-SNPs: The Importance of miR Germ-Line Genetics. Noncoding RNA. 2019 Mar 20; 5(1). Malhotra P, Read GH, Weidhaas JB. PMID: 30897768; PMCID: PMC6468861.
      View in: PubMed   Mentions: 2  
    16. Patient-Reported Outcomes and Cosmesis in a Feasibility Study of 4-Dimensional Simulated Image Guided Accelerated Partial Breast Irradiation. Pract Radiat Oncol. 2019 May; 9(3):e257-e265. Rahimy E, Weidhaas J, Wei W, Lannin D, Horowitz N, Higgins S, Wilson LD, Knowlton C, Moran MS, Young MR, Killelea B, Chagpar A, Yeboa DN, Zelterman D, Evans S. PMID: 30796975.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    17. Functional microRNA binding site variants. Mol Oncol. 2019 01; 13(1):4-8. Yuan Y, Weidhaas JB. PMID: 30536617; PMCID: PMC6322190.
      View in: PubMed   Mentions: 10     Fields:    Translation:Cells
    18. MicroRNA signatures discriminate between uterine and ovarian serous carcinomas. Hum Pathol. 2018 06; 76:133-140. Hui P, Gysler SM, Uduman M, Togun TA, Prado DE, Brambs CE, Nallur S, Schwartz PE, Rutherford TJ, Santin AD, Weidhaas JB, Ratner ES. PMID: 29518404.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    19. The patient's perspective on breast radiotherapy: Initial fears and expectations versus reality. Cancer. 2018 04 15; 124(8):1673-1681. Shaverdian N, Wang X, Hegde JV, Aledia C, Weidhaas JB, Steinberg ML, McCloskey SA. PMID: 29479673.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    20. Assessing the Effect of Lifetime Contralateral Breast Cancer Risk on the Selection of Contralateral Prophylactic Mastectomy for Unilateral Breast Cancer. Clin Breast Cancer. 2018 04; 18(2):e205-e218. Hegde JV, Wang X, Attai DJ, DiNome ML, Kusske A, Hoyt AC, Hurvitz SA, Weidhaas JB, Steinberg ML, McCloskey SA. PMID: 29050918.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    21. Investigating the association of rs2910164 with cancer predisposition in an Irish cohort. Endocr Connect. 2017 Nov; 6(8):614-624. McVeigh TP, Mulligan RJ, McVeigh UM, Owens PW, Miller N, Bell M, Sebag F, Guerin C, Quill DS, Weidhaas JB, Kerin MJ, Lowery AJ. PMID: 28899898; PMCID: PMC5640569.
      View in: PubMed   Mentions: 4  
    22. Regulation of autophagy, NF-κB signaling, and cell viability by miR-124 in KRAS mutant mesenchymal-like NSCLC cells. Sci Signal. 2017 Sep 12; 10(496). Mehta AK, Hua K, Whipple W, Nguyen MT, Liu CT, Haybaeck J, Weidhaas J, Settleman J, Singh A. PMID: 28900044; PMCID: PMC5657393.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    23. Predictors associated with MRI surveillance screening in women with a personal history of unilateral breast cancer but without a genetic predisposition for future contralateral breast cancer. Breast Cancer Res Treat. 2017 Nov; 166(1):145-156. Hegde JV, Wang X, Attai DJ, DiNome ML, Kusske A, Hoyt AC, Hurvitz SA, Weidhaas JB, Steinberg ML, McCloskey SA. PMID: 28702891.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    24. Precision Oncology and Genomically Guided Radiation Therapy: A Report From the American Society for Radiation Oncology/American Association of Physicists in Medicine/National Cancer Institute Precision Medicine Conference. Int J Radiat Oncol Biol Phys. 2018 06 01; 101(2):274-284. Hall WA, Bergom C, Thompson RF, Baschnagel AM, Vijayakumar S, Willers H, Li XA, Schultz CJ, Wilson GD, West CML, Capala J, Coleman CN, Torres-Roca JF, Weidhaas J, Feng FY. PMID: 28964588.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    25. The KRAS-Variant and Cetuximab Response in Head and Neck Squamous Cell Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2017 Apr 01; 3(4):483-491. Weidhaas JB, Harris J, Schaue D, Chen AM, Chin R, Axelrod R, El-Naggar AK, Singh AK, Galloway TJ, Raben D, Wang D, Matthiesen C, Avizonis VN, Manon RR, Yumen O, Nguyen-Tan PF, Trotti A, Skinner H, Zhang Q, Ferris RL, Sidransky D, Chung CH. PMID: 28006059; PMCID: PMC5470422.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    26. Erratum: The Non-Coding RNA Journal Club: Highlights on Recent Papers-4. Non-Coding RNA 2016, 2, 9. Noncoding RNA. 2016 09 30; 2(4). Gautheret D, Taube JH, Mani SA, Santulli G, Cuerda-Gil D, Slotkin RK, Zhang B, Wang Y, Salzman DW, Weidhaas JB. PMID: 29657269; PMCID: PMC5831929.
      View in: PubMed   Mentions: 1  
    27. The Non-Coding RNA Journal Club: Highlights on Recent Papers-4. Noncoding RNA. 2016 Sep 21; 2(3). Gautheret D, Taube JH, Mani SA, Santulli G, Cuerda-Gil D, Slotkin RK, Zhang B, Wang Y, Salzman DW, Weidhaas JB. PMID: 29657267; PMCID: PMC5831907.
      View in: PubMed   Mentions:
    28. Estrogen Drives Cellular Transformation and Mutagenesis in Cells Expressing the Breast Cancer-Associated R438W DNA Polymerase Lambda Protein. Mol Cancer Res. 2016 11; 14(11):1068-1077. Nemec AA, Bush KB, Towle-Weicksel JB, Taylor BF, Schulz V, Weidhaas JB, Tuck DP, Sweasy JB. PMID: 27621267; PMCID: PMC5107123.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    29. cel-mir-237 and its homologue, hsa-miR-125b, modulate the cellular response to ionizing radiation. Oncogene. 2017 01 26; 36(4):512-524. Metheetrairut C, Adams BD, Nallur S, Weidhaas JB, Slack FJ. PMID: 27321180; PMCID: PMC5173455.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    30. miR-34 activity is modulated through 5'-end phosphorylation in response to DNA damage. Nat Commun. 2016 Mar 21; 7:10954. Salzman DW, Nakamura K, Nallur S, Dookwah MT, Metheetrairut C, Slack FJ, Weidhaas JB. PMID: 26996824; PMCID: PMC4802117.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCells
    31. Corrigendum: Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet. 2016 Jan; 48(1):101. Bolton KL, Tyrer J, Song H, Ramus SJ, Notaridou M, Jones C, Sher T, Gentry-Maharaj A, Wozniak E, Tsai YY, Weidhaas J, Paik D, Van Den Berg DJ, Stram DO, Pearce CL, Wu AH, Brewster W, Anton-Culver H, Ziogas A, Narod SA, Levine DA, Kaye SB, Brown R, Paul J, Flanagan J, Sieh W, McGuire V, Whittemore AS, Campbell I, Gore ME, Lissowska J, Yang HP, Medrek K, Gronwald J, Lubinski J, Jakubowska A, Le ND, Cook LS, Kelemen LE, Brooks-Wilson A, Massuger LF, Kiemeney LA, Aben KK, van Altena AM, Houlston R, Tomlinson I, Palmieri RT, Moorman PG, Schildkraut J, Iversen ES, Phelan C, Vierkant RA, Cunningham JM, Goode EL, Fridley BL, Kruger-Kjaer S, Blaeker J, Hogdall E, Hogdall C, Gross J, Karlan BY, Ness RB, Edwards RP, Odunsi K, Moyisch KB, Baker JA, Modugno F, Heikkinenen T, Butzow R, Nevanlinna H, Leminen A, Bogdanova N, Antonenkova N, Doerk T, Hillemanns P, Dürst M, Runnebaum I, Thompson PJ, Carney ME, Goodman MT, Lurie G, Wang-Gohrke S, Hein R, Chang-Claude J, Rossing MA, Cushing-Haugen KL, Doherty J, Chen C, Rafnar T, Besenbacher S, Sulem P, Stefansson K, Birrer MJ, Terry KL, Hernandez D, Cramer DW, Vergote I, Amant F, Lambrechts D, Despierre E, Fasching PA, Beckmann MW, Thiel FC, Ekici AB, Chen X, Australian Ovarian Cancer Study Group, Johnatty SE, Webb PM, Beesley J, Chanock S, Garcia-Closas M, Sellers T, Easton DF, Berchuck A, Chenevix-Trench G, Pharoah PD, Gayther SA. PMID: 26711112.
      View in: PubMed   Mentions: 1     Fields:    
    32. Estrogen withdrawal, increased breast cancer risk and the KRAS-variant. Cell Cycle. 2015; 14(13):2091-9. McVeigh TP, Jung SY, Kerin MJ, Salzman DW, Nallur S, Nemec AA, Dookwah M, Sadofsky J, Paranjape T, Kelly O, Chan E, Miller N, Sweeney KJ, Zelterman D, Sweasy J, Pilarski R, Telesca D, Slack FJ, Weidhaas JB. PMID: 25961464; PMCID: PMC4614527.
      View in: PubMed   Mentions: 7  Translation:HumansCells
    33. Tumor-associated mutations in a conserved structural motif alter physical and biochemical properties of human RAD51 recombinase. Nucleic Acids Res. 2015 Jan; 43(2):1098-111. Chen J, Morrical MD, Donigan KA, Weidhaas JB, Sweasy JB, Averill AM, Tomczak JA, Morrical SW. PMID: 25539919; PMCID: PMC4333388.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    34. A PHASE II TRIAL OF BALLOON-CATHETER PARTIAL BREAST BRACHYTHERAPY OPTIMIZATION IN THE TREATMENT OF STAGE 0, I AND IIA BREAST CARCINOMA. J Radiat Oncol. 2014 Dec; 3(4):371-378. Nath SK, Chen ZJ, Rowe BP, Blitzblau RC, Aneja S, Grube BJ, Horowitz NR, Weidhaas JB. PMID: 25485042; PMCID: PMC4254816.
      View in: PubMed   Mentions:
    35. A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy. Clin Cancer Res. 2014 Sep 01; 20(17):4499-4510. Saridaki Z, Weidhaas JB, Lenz HJ, Laurent-Puig P, Jacobs B, De Schutter J, De Roock W, Salzman DW, Zhang W, Yang D, Pilati C, Bouché O, Piessevaux H, Tejpar S. PMID: 25183481; PMCID: PMC4155520.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCells
    36. A 3'-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol. 2014 Nov; 25(11):2230-2236. Chung CH, Lee JW, Slebos RJ, Howard JD, Perez J, Kang H, Fertig EJ, Considine M, Gilbert J, Murphy BA, Nallur S, Paranjape T, Jordan RC, Garcia J, Burtness B, Forastiere AA, Weidhaas JB. PMID: 25081901; PMCID: PMC4207729.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    37. A germline mutation in the BRCA1 3'UTR predicts Stage IV breast cancer. BMC Cancer. 2014 Jun 10; 14:421. Dorairaj JJ, Salzman DW, Wall D, Rounds T, Preskill C, Sullivan CA, Lindner R, Curran C, Lezon-Geyda K, McVeigh T, Harris L, Newell J, Kerin MJ, Wood M, Miller N, Weidhaas JB. PMID: 24915755; PMCID: PMC4059881.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    38. Targeted resequencing of the microRNAome and 3'UTRome reveals functional germline DNA variants with altered prevalence in epithelial ovarian cancer. Oncogene. 2015 Apr 16; 34(16):2125-37. Chen X, Paranjape T, Stahlhut C, McVeigh T, Keane F, Nallur S, Miller N, Kerin M, Deng Y, Yao X, Zhao H, Weidhaas JB, Slack FJ. PMID: 24909162; PMCID: PMC4326598.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    39. Radiation therapy oncology group gynecologic oncology working group: comprehensive results. Int J Gynecol Cancer. 2014 Jun; 24(5):956-62. Gaffney DK, Jhingran A, Portelance L, Viswanathan A, Schefter T, Weidhaas J, Small W. PMID: 24819663; PMCID: PMC4808297.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    40. The KRAS-variant and miRNA expression in RTOG endometrial cancer clinical trials 9708 and 9905. PLoS One. 2014; 9(4):e94167. Lee LJ, Ratner E, Uduman M, Winter K, Boeke M, Greven KM, King S, Burke TW, Underhill K, Kim H, Boulware RJ, Yu H, Parkash V, Lu L, Gaffney D, Dicker AP, Weidhaas J. PMID: 24732316; PMCID: PMC3986055.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    41. Extensive sequence variation in the 3' untranslated region of the KRAS gene in lung and ovarian cancer cases. Cell Cycle. 2014; 13(6):1030-40. Kim M, Chen X, Chin LJ, Paranjape T, Speed WC, Kidd KK, Zhao H, Weidhaas JB, Slack FJ. PMID: 24552817; PMCID: PMC3984301.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    42. Current status and recommendations for the future of research, teaching, and testing in the biological sciences of radiation oncology: report of the American Society for Radiation Oncology Cancer Biology/Radiation Biology Task Force, executive summary. Int J Radiat Oncol Biol Phys. 2014 Jan 01; 88(1):11-7. Wallner PE, Anscher MS, Barker CA, Bassetti M, Bristow RG, Cha YI, Dicker AP, Formenti SC, Graves EE, Hahn SM, Hei TK, Kimmelman AC, Kirsch DG, Kozak KR, Lawrence TS, Marples B, McBride WH, Mikkelsen RB, Park CC, Weidhaas JB, Zietman AL, Steinberg M. PMID: 24246724.
      View in: PubMed   Mentions: 5     Fields:    Translation:Cells
    43. Ribonucleotide reductase expression in cervical cancer: a radiation therapy oncology group translational science analysis. Int J Gynecol Cancer. 2013 May; 23(4):615-21. Kunos CA, Winter K, Dicker AP, Small W, Abdul-Karim FW, Dawson D, Jhingran A, Valicenti R, Weidhaas JB, Gaffney DK. PMID: 23552804; PMCID: PMC3662019.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    44. SNPs in microRNA binding sites as prognostic and predictive cancer biomarkers. Crit Rev Oncog. 2013; 18(4):327-40. Preskill C, Weidhaas JB. PMID: 23614619; PMCID: PMC4028830.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    45. COX-2 expression and survival in patients with locally advanced cervical cancer treated with chemoradiotherapy and celecoxib: a quantitative immunohistochemical analysis of RTOG C0128. Int J Gynecol Cancer. 2013 Jan; 23(1):176-83. Doll CM, Winter K, Gaffney DK, Ryu JK, Jhingran A, Dicker AP, Weidhaas JB, Miller BE, Magliocco AM. PMID: 23221733; PMCID: PMC4665619.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    46. SNPing cancer in the bud: microRNA and microRNA-target site polymorphisms as diagnostic and prognostic biomarkers in cancer. Pharmacol Ther. 2013 Jan; 137(1):55-63. Salzman DW, Weidhaas JB. PMID: 22964086; PMCID: PMC3546232.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansAnimals
    47. Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma. Proc Natl Acad Sci U S A. 2012 Jun 26; 109(26):E1695-704. Babar IA, Cheng CJ, Booth CJ, Liang X, Weidhaas JB, Saltzman WM, Slack FJ. PMID: 22685206; PMCID: PMC3387084.
      View in: PubMed   Mentions: 185     Fields:    Translation:AnimalsCells
    48. A prospective, multicenter study of complementary/alternative medicine (CAM) utilization during definitive radiation for breast cancer. Int J Radiat Oncol Biol Phys. 2013 Jan 01; 85(1):40-6. Moran MS, Ma S, Jagsi R, Yang TJ, Higgins SA, Weidhaas JB, Wilson LD, Lloyd S, Peschel R, Gaudreau B, Rockwell S. PMID: 22658441.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    49. The KRAS-variant is associated with risk of developing double primary breast and ovarian cancer. PLoS One. 2012; 7(5):e37891. Pilarski R, Patel DA, Weitzel J, McVeigh T, Dorairaj JJ, Heneghan HM, Miller N, Weidhaas JB, Kerin MJ, McKenna M, Wu X, Hildebrandt M, Zelterman D, Sand S, Shulman LP. PMID: 22662244; PMCID: PMC3360659.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    50. A polymorphism in a let-7 microRNA binding site of KRAS in women with endometriosis. EMBO Mol Med. 2012 Mar; 4(3):206-17. Grechukhina O, Petracco R, Popkhadze S, Massasa E, Paranjape T, Chan E, Flores I, Weidhaas JB, Taylor HS. PMID: 22307873; PMCID: PMC3376847.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansAnimalsCells
    51. KRAS alleles: the LCS6 3'UTR variant and KRAS coding sequence mutations in the NCI-60 panel. Cell Cycle. 2012 Jan 15; 11(2):361-6. Kundu ST, Nallur S, Paranjape T, Boeke M, Weidhaas JB, Slack FJ. PMID: 22189714.
      View in: PubMed   Mentions: 13  Translation:HumansCells
    52. A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer. Oncogene. 2012 Oct 18; 31(42):4559-66. Ratner ES, Keane FK, Lindner R, Tassi RA, Paranjape T, Glasgow M, Nallur S, Deng Y, Lu L, Steele L, Sand S, Muller RU, Bignotti E, Bellone S, Boeke M, Yao X, Pecorelli S, Ravaggi A, Katsaros D, Zelterman D, Cristea MC, Yu H, Rutherford TJ, Weitzel JN, Neuhausen SL, Schwartz PE, Slack FJ, Santin AD, Weidhaas JB. PMID: 22139083; PMCID: PMC3342446.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCells
    53. Inhibition of hypoxia-induced miR-155 radiosensitizes hypoxic lung cancer cells. Cancer Biol Ther. 2011 Nov 15; 12(10):908-14. Babar IA, Czochor J, Steinmetz A, Weidhaas JB, Glazer PM, Slack FJ. PMID: 22027557; PMCID: PMC3280906.
      View in: PubMed   Mentions: 66     Fields:    Translation:HumansCells
    54. KRAS rs61764370 in Epithelial Ovarian Cancer-Letter. Clin Cancer Res. 2011 Oct 15; 17(20):6600; author reply 6601. Weidhaas JB, Slack FJ. PMID: 22003074.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    55. A let-7 microRNA SNP in the KRAS 3'UTR is prognostic in early-stage colorectal cancer. Clin Cancer Res. 2011 Dec 15; 17(24):7723-31. Smits KM, Paranjape T, Nallur S, Wouters KA, Weijenberg MP, Schouten LJ, van den Brandt PA, Bosman FT, Weidhaas JB, van Engeland M. PMID: 21994416; PMCID: PMC5919188.
      View in: PubMed   Mentions: 48     Fields:    Translation:Humans
    56. miRNAs in the spotlight: Making 'silent' mutations speak up. Nat Med. 2011 Aug 04; 17(8):934-5. Salzman DW, Weidhaas JB. PMID: 21818091.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimals
    57. MicroRNA signatures differentiate melanoma subtypes. Cell Cycle. 2011 Jun 01; 10(11):1845-52. Chan E, Patel R, Nallur S, Ratner E, Bacchiocchi A, Hoyt K, Szpakowski S, Godshalk S, Ariyan S, Sznol M, Halaban R, Krauthammer M, Tuck D, Slack FJ, Weidhaas JB. PMID: 21543894; PMCID: PMC3233487.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansCells
    58. The Holman Research Pathway in radiation oncology. Int J Radiat Oncol Biol Phys. 2011 Jun 01; 80(2):321-3. Weidhaas JB, Kirsch DG. PMID: 21549248; PMCID: PMC3677819.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    59. Characteristics and outcomes of breast cancer in women with and without a history of radiation for Hodgkin's lymphoma: a multi-institutional, matched cohort study. J Clin Oncol. 2011 Jun 20; 29(18):2466-73. Elkin EB, Klem ML, Gonzales AM, Ishill NM, Hodgson D, Ng AK, Marks LB, Weidhaas J, Freedman GM, Miller RC, Constine LS, Myrehaug S, Yahalom J. PMID: 21576642; PMCID: PMC3138631.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    60. A 3'-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis. Lancet Oncol. 2011 Apr; 12(4):377-86. Paranjape T, Heneghan H, Lindner R, Keane FK, Hoffman A, Hollestelle A, Dorairaj J, Geyda K, Pelletier C, Nallur S, Martens JW, Hooning MJ, Kerin M, Zelterman D, Zhu Y, Tuck D, Harris L, Miller N, Slack F, Weidhaas J. PMID: 21435948; PMCID: PMC3488438.
      View in: PubMed   Mentions: 66     Fields:    Translation:Humans
    61. Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol Ther. 2011 Jun; 19(6):1116-22. Trang P, Wiggins JF, Daige CL, Cho C, Omotola M, Brown D, Weidhaas JB, Bader AG, Slack FJ. PMID: 21427705; PMCID: PMC3129804.
      View in: PubMed   Mentions: 254     Fields:    Translation:HumansAnimalsCells
    62. Cancer microRNAs: from subtype profiling to predictors of response to therapy. Trends Mol Med. 2011 May; 17(5):235-43. Chan E, Prado DE, Weidhaas JB. PMID: 21354374; PMCID: PMC3092835.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    63. Rare BRCA1 haplotypes including 3'UTR SNPs associated with breast cancer risk. Cell Cycle. 2011 Jan 01; 10(1):90-9. Pelletier C, Speed WC, Paranjape T, Keane K, Blitzblau R, Hollestelle A, Safavi K, van den Ouweland A, Zelterman D, Slack FJ, Kidd KK, Weidhaas JB. PMID: 21191178; PMCID: PMC3048078.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    64. MicroRNA binding-site polymorphisms as potential biomarkers of cancer risk. Mol Diagn Ther. 2010 Dec 01; 14(6):335-42. Blitzblau RC, Weidhaas JB. PMID: 21275451.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    65. A Variant in a MicroRNA complementary site in the 3' UTR of the KIT oncogene increases risk of acral melanoma. Oncogene. 2011 Mar 31; 30(13):1542-50. Godshalk SE, Paranjape T, Nallur S, Speed W, Chan E, Molinaro AM, Bacchiocchi A, Hoyt K, Tworkoski K, Stern DF, Sznol M, Ariyan S, Lazova R, Halaban R, Kidd KK, Weidhaas JB, Slack FJ. PMID: 21119596; PMCID: PMC3069149.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    66. Genetic and epigenetic association studies suggest a role of microRNA biogenesis gene exportin-5 (XPO5) in breast tumorigenesis. Int J Mol Epidemiol Genet. 2011 Jan 01; 2(1):9-18. Leaderer D, Hoffman AE, Zheng T, Fu A, Weidhaas J, Paranjape T, Zhu Y. PMID: 21552306; PMCID: PMC3077234.
      View in: PubMed   Mentions: 29  
    67. Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet. 2010 Oct; 42(10):880-4. Bolton KL, Tyrer J, Song H, Ramus SJ, Notaridou M, Jones C, Sher T, Gentry-Maharaj A, Wozniak E, Tsai YY, Weidhaas J, Paik D, Van Den Berg DJ, Stram DO, Pearce CL, Wu AH, Brewster W, Anton-Culver H, Ziogas A, Narod SA, Levine DA, Kaye SB, Brown R, Paul J, Flanagan J, Sieh W, McGuire V, Whittemore AS, Campbell I, Gore ME, Lissowska J, Yang HP, Medrek K, Gronwald J, Lubinski J, Jakubowska A, Le ND, Cook LS, Kelemen LE, Brooks-Wilson A, Brook-Wilson A, Massuger LF, Kiemeney LA, Aben KK, van Altena AM, Houlston R, Tomlinson I, Palmieri RT, Moorman PG, Schildkraut J, Iversen ES, Phelan C, Vierkant RA, Cunningham JM, Goode EL, Fridley BL, Kruger-Kjaer S, Blaeker J, Hogdall E, Hogdall C, Gross J, Karlan BY, Ness RB, Edwards RP, Odunsi K, Moyisch KB, Baker JA, Modugno F, Heikkinenen T, Butzow R, Nevanlinna H, Leminen A, Bogdanova N, Antonenkova N, Doerk T, Hillemanns P, Dürst M, Runnebaum I, Thompson PJ, Carney ME, Goodman MT, Lurie G, Wang-Gohrke S, Hein R, Chang-Claude J, Rossing MA, Cushing-Haugen KL, Doherty J, Chen C, Rafnar T, Besenbacher S, Sulem P, Stefansson K, Birrer MJ, Terry KL, Hernandez D, Cramer DW, Vergote I, Amant F, Lambrechts D, Despierre E, Fasching PA, Beckmann MW, Thiel FC, Ekici AB, Chen X, Australian Ovarian Cancer Study Group, Australian Cancer Study (Ovarian Cancer), Ovarian Cancer Association Consortium, Johnatty SE, Webb PM, Beesley J, Chanock S, Garcia-Closas M, Sellers T, Easton DF, Berchuck A, Chenevix-Trench G, Pharoah PD, Gayther SA. PMID: 20852633; PMCID: PMC3125495.
      View in: PubMed   Mentions: 150     Fields:    Translation:HumansCells
    68. MicroRNA binding site polymorphisms as biomarkers of cancer risk. Expert Rev Mol Diagn. 2010 Sep; 10(6):817-29. Pelletier C, Weidhaas JB. PMID: 20843204; PMCID: PMC3832135.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCells
    69. Prevalence of the variant allele rs61764370 T>G in the 3'UTR of KRAS among Dutch BRCA1, BRCA2 and non-BRCA1/BRCA2 breast cancer families. Breast Cancer Res Treat. 2011 Jul; 128(1):79-84. Hollestelle A, Pelletier C, Hooning M, Crepin E, Schutte M, Look M, Collee JM, Nieuwlaat A, Dorssers LC, Seynaeve C, Aulchenko YS, Martens JW, van den Ouweland AM, Weidhaas JB. PMID: 20676756; PMCID: PMC3735357.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    70. A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk. Cancer Res. 2010 Aug 15; 70(16):6509-15. Ratner E, Lu L, Boeke M, Barnett R, Nallur S, Chin LJ, Pelletier C, Blitzblau R, Tassi R, Paranjape T, Hui P, Godwin AK, Yu H, Risch H, Rutherford T, Schwartz P, Santin A, Matloff E, Zelterman D, Slack FJ, Weidhaas JB. PMID: 20647319; PMCID: PMC2923587.
      View in: PubMed   Mentions: 65     Fields:    Translation:Humans
    71. MicroRNA signatures differentiate uterine cancer tumor subtypes. Gynecol Oncol. 2010 Sep; 118(3):251-7. Ratner ES, Tuck D, Richter C, Nallur S, Patel RM, Schultz V, Hui P, Schwartz PE, Rutherford TJ, Weidhaas JB. PMID: 20542546; PMCID: PMC2918705.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansCells
    72. Using microRNAs to understand cancer biology. Lancet Oncol. 2010 Feb; 11(2):106-7. Weidhaas J. PMID: 20022811; PMCID: PMC5919278.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    73. Regression of murine lung tumors by the let-7 microRNA. Oncogene. 2010 Mar 18; 29(11):1580-7. Trang P, Medina PP, Wiggins JF, Ruffino L, Kelnar K, Omotola M, Homer R, Brown D, Bader AG, Weidhaas JB, Slack FJ. PMID: 19966857; PMCID: PMC2841713.
      View in: PubMed   Mentions: 220     Fields:    Translation:HumansAnimalsCells
    74. MicroRNAs: tools for cancer diagnostics. Gut. 2009 Nov; 58(11):1546-54. Paranjape T, Slack FJ, Weidhaas JB. PMID: 19834118; PMCID: PMC2802653.
      View in: PubMed   Mentions: 53     Fields:    Translation:HumansCells
    75. microRNA miR-196a-2 and breast cancer: a genetic and epigenetic association study and functional analysis. Cancer Res. 2009 Jul 15; 69(14):5970-7. Hoffman AE, Zheng T, Yi C, Leaderer D, Weidhaas J, Slack F, Zhang Y, Paranjape T, Zhu Y. PMID: 19567675; PMCID: PMC2716085.
      View in: PubMed   Mentions: 162     Fields:    Translation:HumansCells
    76. Changes in gene expression predicting local control in cervical cancer: results from Radiation Therapy Oncology Group 0128. Clin Cancer Res. 2009 Jun 15; 15(12):4199-206. Weidhaas JB, Li SX, Winter K, Ryu J, Jhingran A, Miller B, Dicker AP, Gaffney D. PMID: 19509178; PMCID: PMC2758917.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    77. The mir-34 microRNA is required for the DNA damage response in vivo in C. elegans and in vitro in human breast cancer cells. Oncogene. 2009 Jun 25; 28(25):2419-24. Kato M, Paranjape T, Müller RU, Ullrich R, Nallur S, Gillespie E, Keane K, Esquela-Kerscher A, Weidhaas JB, Slack FJ. PMID: 19421141; PMCID: PMC2941141.
      View in: PubMed   Mentions: 103     Fields:    Translation:HumansAnimalsCells
    78. Preoperative chemotherapy decreases the need for re-excision of breast cancers between 2 and 4 cm diameter. Ann Surg Oncol. 2009 Mar; 16(3):697-702. Christy CJ, Thorsteinsson D, Grube BJ, Black D, Abu-Khalaf M, Chung GG, DiGiovanna MP, Miller K, Higgins SA, Weidhaas J, Harris L, Tavassoli FA, Lannin DR. PMID: 19132447.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    79. MicroRNA in cancer prognosis. N Engl J Med. 2008 Dec 18; 359(25):2720-2. Slack FJ, Weidhaas JB. PMID: 19092157.
      View in: PubMed   Mentions: 76     Fields:    Translation:Humans
    80. MicroRNAs as potential cancer therapeutics. Oncogene. 2008 Dec; 27 Suppl 2:S52-7. Trang P, Weidhaas JB, Slack FJ. PMID: 19956180.
      View in: PubMed   Mentions: 111     Fields:    Translation:HumansAnimals
    81. A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk. Cancer Res. 2008 Oct 15; 68(20):8535-40. Chin LJ, Ratner E, Leng S, Zhai R, Nallur S, Babar I, Muller RU, Straka E, Su L, Burki EA, Crowell RE, Patel R, Kulkarni T, Homer R, Zelterman D, Kidd KK, Zhu Y, Christiani DC, Belinsky SA, Slack FJ, Weidhaas JB. PMID: 18922928; PMCID: PMC2672193.
      View in: PubMed   Mentions: 293     Fields:    Translation:Humans
    82. Postmastectomy radiation therapy for lymph node-negative, locally advanced breast cancer after modified radical mastectomy: analysis of the NCI Surveillance, Epidemiology, and End Results database. Cancer. 2008 Jul 01; 113(1):38-47. Yu JB, Wilson LD, Dasgupta T, Castrucci WA, Weidhaas JB. PMID: 18442108.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    83. Breast sentinel lymph node dissection before preoperative chemotherapy. Arch Surg. 2008 Jul; 143(7):692-9; discussion 699-700. Grube BJ, Christy CJ, Black D, Martel M, Harris L, Weidhaas J, Digiovanna MP, Chung G, Abu-Khalaf MM, Miller KD, Higgins SA, Philpotts L, Tavassoli FA, Lannin DR. PMID: 18645113.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    84. miRNA modulation of the cellular stress response. Future Oncol. 2008 Apr; 4(2):289-98. Babar IA, Slack FJ, Weidhaas JB. PMID: 18407740.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansAnimals
    85. The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle. 2008 Mar 15; 7(6):759-64. Esquela-Kerscher A, Trang P, Wiggins JF, Patrawala L, Cheng A, Ford L, Weidhaas JB, Brown D, Bader AG, Slack FJ. PMID: 18344688.
      View in: PubMed   Mentions: 254     Fields:    Translation:HumansAnimalsCells
    86. MicroRNAs as potential agents to alter resistance to cytotoxic anticancer therapy. Cancer Res. 2007 Dec 01; 67(23):11111-6. Weidhaas JB, Babar I, Nallur SM, Trang P, Roush S, Boehm M, Gillespie E, Slack FJ. PMID: 18056433; PMCID: PMC6070379.
      View in: PubMed   Mentions: 188     Fields:    Translation:HumansAnimalsCells
    87. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol. 2006 Dec 20; 24(36):5652-7. Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, Harris L, Hait W, Toppmeyer D. PMID: 17116942.
      View in: PubMed   Mentions: 356     Fields:    Translation:Humans
    88. A conserved RAS/mitogen-activated protein kinase pathway regulates DNA damage-induced cell death postirradiation in Radelegans. Cancer Res. 2006 Nov 01; 66(21):10434-8. Weidhaas JB, Eisenmann DM, Holub JM, Nallur SV. PMID: 17079464.
      View in: PubMed   Mentions: 11     Fields:    Translation:AnimalsCells
    89. A Caenorhabditis elegans tissue model of radiation-induced reproductive cell death. Proc Natl Acad Sci U S A. 2006 Jun 27; 103(26):9946-51. Weidhaas JB, Eisenmann DM, Holub JM, Nallur SV. PMID: 16788064; PMCID: PMC1502559.
      View in: PubMed   Mentions: 19     Fields:    Translation:AnimalsCells
    90. MicroRNAs as a potential magic bullet in cancer. Future Oncol. 2006 Feb; 2(1):73-82. Slack FJ, Weidhaas JB. PMID: 16556074.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansAnimals
    Joanne's Networks
    Concepts (343)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (42)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCLA Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version v3.1.0-871-g21b54b14 on PROFILES-PWEB02.

    Copyright © The Regents of the University of California